Anti-cancer approach with NK4: Bivalent action and mechanisms

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 1, 2010, Pages 36-46

  Nakamura, Takahiro ^a   Sakai, Katsuya ^b   Nakamura, Toshikazu ^b   Matsumoto, Kunio ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

Hepatocyte growth factor; Invasion; Met; Metastasis; NK4; Tumor angiogenesis; Tumor initiating cell.

Indexed keywords

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; BASIC FIBROBLAST GROWTH FACTOR; CISPLATIN; CYTOKINE RECEPTOR ANTAGONIST; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FIBRONECTIN; GEFITINIB; GEMCITABINE; INTEGRIN; NK 4; PERLECAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEINASE; RECOMBINANT SCATTER FACTOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ACUTE KIDNEY FAILURE; AMINO TERMINAL SEQUENCE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; BINDING AFFINITY; BREAST CANCER; CANCER GENE THERAPY; CANCER INHIBITION; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STEM CELL; CELL HYPOXIA; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLON CARCINOMA; CONCENTRATION RESPONSE; DENDRITIC CELL; DRUG BINDING; DRUG MECHANISM; DRUG STRUCTURE; ENDOTHELIUM CELL; EXTRACELLULAR SPACE; FIBROBLAST; GALLBLADDER CANCER; GLIOBLASTOMA; HUMAN; IMMUNOREACTIVITY; INFLAMMATORY CELL; KRINGLE DOMAIN; LIVER CELL CARCINOMA; LUNG CANCER; LYMPHANGIOGENESIS; LYMPHOMA; MELANOMA; METASTASIS; MICROTUBULE ASSEMBLY; MOUTH CARCINOMA; MULTIPLE MYELOMA; OVARY CANCER; PANCREAS CANCER; PATHOPHYSIOLOGY; PROSTATE CANCER; PROTEIN ASSEMBLY; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; SKIN ULCER; SQUAMOUS CELL CARCINOMA; STOMACH CANCER;

EID: 77950823134     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871520611009010036     Document Type: Review

References (96)

1. Nakamura, T.; Nawa, K.; Ichihara, A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. Biochem. Biophys. Res. Commun., 1984, 122(3), 1450-1459.
2. Nakamura, T.; Nishizawa, T.; Hagiya, M.; Seki, T.; Shimonishi, M.; Sugimura, A.; Tashiro, K.; Shimizu, S. Molecular cloning and expression of human hepatocyte growth factor. Nature, 1989, 342 (6248), 440-443.
3. Miyazawa, K.; Tsubouchi, H.; Naka, D.; Takahashi, K.; Okigaki, M.; Arakaki, N.; Nakayama, H.; Hirono, S.; Sakiyama, O.; Takahashi, K.; Gohda, E.; Daikuhara, Y.; Kitamura, N. Molecular cloning and sequence analysis of cDNA for human hepatocyte growth factor. Biochem. Biophys. Res. Commun., 1989, 163(2), 967-973.
4. Matsumoto, K.; Nakamura, T. Hepatocyte growth factor (HGF) as tissue organizer for organogenesis and regeneration. Biochem. Biophys. Res. Commun., 1997, 239(3), 639-644.
5. Huh, C.G.; Factor, V.M.; Sánchez, A.; Uchida, K.; Conner, E.A.; Thorgeirsson, S.S. Hepatocyte growth factor/c-met signaling pathway is required for efficient liver regeneration and repair. Proc. Natl. Acad. Sci. USA, 2004, 101(13), 4477-4482.
6. Borowiak, M.; Garratt, A.N.; Wüstefeld, T.; Strehle, M.; Trautwein, C.; Birchmeier, C. Met provide essential signals for liver regeneration. Proc. Natl. Acad. Sci. USA, 2004, 101(29), 10608-10613.
7. Birchmeier, C.; Birchmeier, W.; Gherardi, E.; Vande Woude, G.F. Met, metastasis, motility and more. Nat. Rev. Mol. Cell. Biol., 2003, 4(12), 915-925.
8. Bladt, F.; Riethmacher, D.; Isenmann, S.; Aguzzi, A.; Birchmeier, C. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature, 1995, 376(6543), 768-771.
9. Montesano, R.; Matsumoto, K.; Nakamura, T.; Orci, L. Identification of a fibroblast-derived epithelial morphogen as hepatocyte growth factor. Cell, 1991, 67(5), 901-908.
10. Kadono, Y.; Shibahara, K.; Namiki, M.; Watanabe, Y.; Seiki, M.; Sato, H. Membranetype-1-matrix metalloproteinase is involved in the formation of hepatocyte growth factor/scatter factor-induced branching tubules in madin-darby canine kidney epithelial cells. Biochem. Biophys. Res. Commun., 1998, 251(3), 681-687.
11. Hotary, K.; Allen, E.; Punturieri, A.; Yana, I.; Weiss, S.J. Regulation of cells invasion and morphogenesis in a three-dimensional type I collagen matrix by membrane-type matrix metalloproteinases 1, 2, and 3. J. Cell Biol., 2000, 149(6), 1309-1323.
12. Jiang, W.G.; Martin, T.A.; Parr, C.; Davies, G.; Matsumoto, K,; Nakamura, T. Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit. Rev. Oncol. Hematol., 2005, 53(1), 35-69.
13. Bussolino, F.; Di Renzo, M.F.; Ziche, M.; Bochietto, E.; Olivero, M.; Naldini, L.; Gaudino, G.; Tamagnone, L.; Coffer, A.; Comoglio, P.M. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J. Cell Biol., 1992, 119(3), 629-641.
14. Kajiya, K.; Hirakawa, S.; Ma, B.; Drinnenberg, I.; Detmar, M. Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J., 2005, 24(16), 2885-2895.
15. Jiang, W.G.; Davies, G.; Martin, T.A.: Parr, C.; Watkins, G.; Mansel, R.E.; Mason, M.D. The potential lymphangiogenic effects of hepatocyte growth factor/scatter factor in vitro and in vivo. Int. J. Mol. Med., 2005, 16(4), 723-728.
16. Engelman, J.A.; Zejnullahu, K.; Mitsudomi, T.; Song, Y.; Hyland, C.; Park, J.O.; Lindeman, N.; Gale, C.M.; Zhao, X.; Christensen, J.; Kosaka, T.; Holmes, A.J.; Rogers, A.M.; Cappuzzo, F.; Mok, T.; Lee, C.; Johnson, B.E.; Cantley, L.C.; Jänne, P.A. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science, 2007, 316(5827), 1039-1043.
17. Yano, S.; Wang, W.; Li, Q.; Matsumoto, K.; Sakurama, H.; Nakamura, T.; Ogino, H.; Kakiuchi, S.; Hanibuchi, M.; Nishioka, Y.; Uehara, H.; Mitsudomi, T.; Yatabe, Y.; Nakamura, T.; Sone, S. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with EGF Receptor activating mutations. Cancer Res., 2008, 68(22), 6479-6487.
18. Ohuchida, K.; Mizumoto, K.; Murakami, M.; Qian, L.W.; Sato, N.; Nagai, E.; Matsumoto, K.; Nakamura, T.; Tanaka, M. Radiation to stromal fibroblasts increases invasiveness of pancreatic cancer cells through tumor-stromal interactions. Cancer Res., 2004, 64(9), 3215-3222. (Pubitemid 38581425)
19. Matsumoto, K.; Nakamura, T. Hepatocyte growth factor and the Met system as a mediator of tumor-stromal interactions. Int. J.Cancer, 2006, 119(3), 477-483.
20. Comoglio, P.M.; Giordano, S.; Trusolino, L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat. Rev. Drug Discov., 2008, 7(6), 504-516.
21. Knudsen, B.S.; Vande Woude, G. Showering c-MET-dependent cancer with drugs. Curr. Opin. Genet. Dev., 2008, 18(1), 87-96.
22. Date, K.; Matsumoto, K.; Shimura, H.; Tanaka, M.; Nakamura, T. HGF/NK4 is a specific antagonist for pleiotrophic actions of hepatocyte growth factor. FEBS Lett., 1997, 420(1), 1-6.
23. Kuba, K.; Matsumoto, K.; Date, K.; Shimura, H.; Tanaka, M.; Nakamura, T. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice. Cancer Res., 2000, 60(23), 6737-6743.
24. Sakai, K.; Nakamura, T.; Matsumoto, K.; Nakamura, T. Angioinhibitory action of NK4 involves impaired extracellular assembly of fibronectin mediated by perlecan-NK4 association. J. Biol. Chem., 2009, 284(33), 22491-22499.
25. Müller, M.M.; Fusenig, N.E. Friends or foes - bipolar effects of the tumour stroma in cancer. Nat. Rev. Cancer, 2004, 4(11), 839-849.
26. Bhowmick, N.A.; Neilson, E.G.; Moses, H.L. Stromal fibroblasts in cancer initiation and progression. Nature, 2004, 432(7015), 332-337.
27. Matsumoto, K.; Horikoshi, M.; Rikimaru, K.; Enomoto, S. A study of an in vitro model for invasion of oral squamous cell carcinoma. J. Oral Pathol. Med., 1989, 18(9), 498-501.
28. Matsumoto, K.; Matsumoto, K.; Nakamura, T.; Kramer, R.H. Hepatocyte growth factor/scatter factor induces tyrosine phosphorylation of focal adhesion kinase (p125FAK) and promotes migration and invasion by oral squamous cell carcinoma cells. J. Biol. Chem., 1994, 269(50), 31807-31813.
29. Weidner, K.M.; Behrens, J.; Vandekerckhove, J.; Birchmeier, W. Scatter factor: molecular characteristics and effect on the invasiveness of epithelial cells. J. Cell Biol., 1990, 111(5 Pt 1), 2097-2108.
30. Christensen, J.G.; Burrows, J.; Salgia, R. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention. Cancer Lett., 2005, 225(1), 1-26.
31. Rosen, J.M.; Jordan, C.T. The increasing complexity of the cancer stem cell paradigm. Science, 2009, 324(5935), 1670-1673.
32. Tamase, A.; Muraguchia, T.; Naka, K.; Tanaka, S.; Kinoshita, M.; Hoshii, T.; Ohmura, M.; Shugo, H.; Ooshio, T.; Nakada, M.; Sawamoto, K.; Onodera, M.; e, Matsumoto, K.; Oshima, M.; Asano, M.; Saya, H.; Okano, H.; Suda, T.; Hamada, J.; Hirao, A.Identification of tumor-initiating cells in a highly aggressive brain tumor using promoter activity of nucleostemin. Proc. Natl. Acad. Sci. USA, 2009, 106(40), 17163-17168.
33. Camphausen, K.; Moses, M.A.; Beecken, W.D.; Khan, M.K.; Folkman, J.; O'Reilly, M.S. Radiation therapy to a primary tumor accelerates metastatic growth in mice. Cancer Res., 2001, 61(5), 2207-2211.
34. Wild-Bode, C.; Weller, M.; Rimner, A.; Dichgans, J.; Wick, W. Sublethal irradiation promotes migration and invasiveness of glioma cells: implications for radiotherapy of human glioblastoma. Cancer Res., 2001, 61(6), 2744-2750.
35. Bao, S.; Wu, Q.; McLendon, R.E.; Hao, Y.; Shi, Q.; Hjelmeland, A.B.; Dewhirst, M.W.; Bigner, D.D.; Rich, J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature, 2006, 444(7120), 756-760.
36. Phillips, T.M.; McBride, W.H.; Pajonk, F. The response of CD24(- /low)/CD44+ breast cancer-initiating cells to radiation. J. Natl. Cancer Inst., 2006, 98(24), 1777-1785.
37. Baumann, M.; Krause, M.; Hill R. Exploring the role of cancer stem cells in radioresistance. Nat. Rev. Cancer, 2008, 8(7), 545-554.
38. Höckel, M.; Vaupel, P. Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J. Natl. Cancer Inst., 2001, 93(4), 266-276.
39. Postovit, L.M.; Adams, M.A.; Lash, G.E.; Heaton, J.P.; Graham, C.H. Oxygen-mediated regulation of tumor cell invasiveness. Involvement of a nitric oxide signaling pathway. J. Biol. Chem., 2002, 277(38), 35730-35737.
40. Pennacchietti, S.; Michieli, P.; Galluzzo, M.; Mazzone, M.; Giordano, S.; Comoglio, P.M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell, 2003, 3(4), 347-3461.
41. Lokker, N.A.; Mark, M.R.; Luis, E.A.; Bennett, G.L.; Robbins, K.A.; Baker, J.B.; Godowski, P.J. Structure-function analysis of hepatocyte growth factor: identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J., 1992, 11(7), 2503-2510.
42. Cioce, V.; Csaky, K.G.; Chan, A.M.L.; Bottaro, D.P.; Taylor, W.G.; Jensen, R.; Aaronson, S.A.; Rubin, J.S. Hepatocyte growth factor (HGF)/NK1 is a naturally occurring HGF/scatter factor variant with partial agonist/antagonist activity. J. Biol. Chem., 1996, 271(22), 13110-13115.
43. Matsumoto, K.; Kataoka, H.; Date, K.; Nakamura, T. Cooperative interaction between alpha-chain and beta-chain of HGF on c-Met receptor confers ligand-induced receptor tyrosine phosphorylation and multiple biological responses. J. Biol. Chem., 1998, 273(36), 22913-22920.
44. Gherardi, E.; Sandin, S.; Petoukhov, M.V.; Finch, J.; Youles. M.E.; Ofverstedt, L.G.; Miguel, R.N.; Blundell, T.L.; Vande Woude, G.F.; Skoglund, U.; Svergun, D.I. Structural basis of hepatocyte growth factor/scatter factor and MET signalling. Proc. Natl. Acad. Sci. USA, 2006, 103(11), 4046-4051.
45. Basilico, C.; Arnesano, A.; Galluzzo, M.; Comoglio, P.M.; Michieli, P. A high affinity hepatocyte growth factor-binding site in the immunoglobulin-like region of Met. J. Biol. Chem., 2008, 283(30), 21267-21277.
46. Schwall, R.H.; Chang, L.Y.; Godowski, P.J.; Kahn, D.W. Hillan, K.J.; Bauer, K.D.; Zioncheck, T.F. Heparin induces dimerization and confers proliferative activity onto the hepatocyte growth factor antagonists NK1 and NK2. J. Cell Biol., 1996, 133(3), 709-718.
47. Silvagno, F.; Follenzi, A.; Arese, M.; Prat, M.; Giraudo, E.; Gaudino, G.; Camussi, G.; Comoglio, P.M.; Bussolino, F. In vivo activation of met tyrosine kinase by heterodimeric hepatocyte growth factor molecule promotes angiogenesis, Arterioscler. Thromb. Vasc. Biol., 1995, 15(11), 1857-1865.
48. Date, K.; Matsumoto, K.; Kuba, K.; Shimura, H.; Tanaka, M.; Nakamura, T. Inhibition of tumor growth and invasion by a fourkringle antagonist (HGF/NK4) for hepatocyte growth factor. Oncogene, 1998, 17(23), 3045-3054.
49. Matsumoto, K.; Nakamura, T.; Sakai, K.; Nakamura, T. Hepatocyte growth factor and met in tumor biology and therapeutic approach with NK4. Proteomics, 2008, 8(16), 3360-3370.
50. Grant, D.S.; Kleinman, H.K.; Goldberg, I.D.; Bhargava, M.M.; Nickoloff, B.J.; Kinsella, J.L.; Polverini, P.; Rosen, E.M. Scatter factor induces blood vessel formation in vivo. Proc. Natl. Acad. Sci. USA, 1993, 90(5), 1937-1941.
51. Knox, S.M.; Whitelock, J.M. Perlecan: how does one molecule do so many things? Cell Mol. Life Sci., 2006, 63(21), 2435-2445.
52. Farach-Carson, M.C.; Carson, D.D. Perlecan - a multifunctional extracellular proteoglycan scaffold. Glycobiology, 2007, 17(9), 897-905.
53. Kalluri, R. Basement membranes: structure, assembly and role in tumor angiogenesis. Nat. Rev. Cancer, 2003, 3(6), 422-433.
54. Hodivala-Dilke, K.M.; Reynolds, A.R.; Reynolds, L.E. Integrins in angiogenesis: multitalented molecules in a balancing act. Cell Tissue Res., 2003, 314(1), 131-144.
55. Kuba, K.; Matsumoto, K.; Ohnishi, K.; Shiratsuchi, T.; Tanaka, M.; Nakamura, T. Kringle 1-4 of hepatocyte growth factor inhibits proliferation and migration of human microvascular endothelial cells. Biochem. Biophys. Res. Commun., 2000, 279(3), 846-852.
56. Xin, L.; Xu, R.; Zhang, Q.; Li, T.; Gan, R. Kringle 1 of human hepatocyte growth factor inhibits bovine aortic endothelial cell proliferation stimulated by basic fibroblast growth factor and causes cell apoptosis. Biochem. Biophys. Res. Commun., 2000, 277(1), 186-190.
57. Shen, Z.; Yang, Z.F.; Gao, Y.; Li, J.C.; Chen, H.X.; Liu, C.C.; Poon, R.T.; Fan, S.T.; Luk, J.M.; Sze, K.H.; Li, T.P.; Gan, R.B.; He, M.L.; Kung, H.F.; Lin, M.C. The kringle 1 domain of hepatocyte growth factor has antiangiogenic and antitumor cell effects on hepatocellular carcinoma. Cancer Res., 2008, 68(2), 404-414.
58. Merkulova-Rainon, T.; England, P.; Ding, S.; Demerens, C.; Tobelem, G. The N-terminal domain of hepatocyte growth factor inhibits the angiogenic behavior of endothelial cells independently from binding to the c-met receptor. J. Biol. Chem., 2003, 278(39), 37400-37408.
59. Mizuno, K.; Inoue, H.; Hagiya, M.; Shimizu, S.; Nose, T.; Shimohigashi, Y.; Nakamura, T. Hairpin loop and second kringle domain are essential sites for heparin binding and biological activity of hepatocyte growth factor. J. Biol. Chem., 1994, 269(2), 1131-1136.
60. Raymond, W.W.; Cruz, A.C.; Caughey, G.H. Mast cell and neutrophil peptidases attack an inactivation segment in hepatocyte growth factor to generate NK4-like antagonists. J. Biol. Chem., 2006, 281(3), 1489-1494.
61. Buchstein, N.; Hoffmann, D.; Smola, H.; Lang, S.; Paulsson, M.; Niemann, C.; Krieg, T.; Eming, S.A. Alternative proteolytic processing of hepatocyte growth factor during wound repair. Am. J. Pathol., 2009, 174(6), 2116-2128.
62. Wright, T.G.; Singh, V.K.; Li, J.J.; Foley, J.H.; Miller, F.; Jia, Z.; Elliott, B.E. Increased production and secretion of HGF alphachain and an antagonistic HGF fragment in a human breast cancer progression model. Int. J. Cancer, 2009, 125(5), 1004-1015.
63. Martin, T.A.; Parr, C.; Davies, G.; Watkins, G.; Lane, J.; Matsumoto, K.; Nakamura, T.; Mansel, R.E.; Jiang, W.G. Growth and angiogenesis of human breast cancer in a nude mouse tumour model is reduced by NK4, the HGF/SF antagonist. Carcinogenesis, 2003, 24(8), 1317-1323.
64. Wen, J.; Matsumoto, K.; Taniura, N.; Tomioka, D.; Nakamura, T. Hepatic gene expression of NK4; an HGF-antagonist/angiogenesis inhibitor, suppresses liver metastasis and invasive growth of colon cancer in mice. Cancer Gene Ther., 2004, 11(6), 419-430.
65. Maemondo, M.; Narumi, K.; Saijo, Y.; Usui, K.; Tahara, M.; Tazawa, R.; Hagiwara, K.; Matsumoto, K.; Nakamura, T.; Nukiwa, T. Targeting angiogenesis and HGF function using an adenoviral vector expressing the HGF-antagonist NK4 for cancer therapy. Mol. Ther., 2002, 5(2), 177-185.
66. Kikuchi, T.; Maemondo, M.; Narumi, K.; Matsumoto, K.; Nakamura, T.; Nukiwa, T. Tumor suppression induced by intratumor administration of adenovirus vector expressing NK4, a 4-kringle antagonist of hepatocyte growth factor, and naïve dendritic cells. Blood, 2002, 100(12), 3950-3959.
67. Wen, J.; Matsumoto, K.; Taniura, N.; Tomioka, D.; Nakamura, T. Inhibition of colon cancer growth and metastasis by NK4 gene repetitive delivery in mice. Biochem., Biophys. Res. Commun., 2007, 358(1), 117-123.
68. Kubota, T.; Fujiwara, H.; Amaike, H.; Takashima, K.; Inada, S.; Atsuji, K.; Yoshimura, M.; Matsumoto, K.; Nakamura, T.; Yamagishi, H. Reduced HGF expression in subcutaneous CT26 tumor genetically modified to secrete NK4 and its possible relation with antitumor effects. Cancer Sci., 2004, 95(4), 321-327.
69. Yoshimura, M.; Fujiwara, H.; Kubota, T.; Amaike, H.; Takashima, K.; Inada, S.; Atsuji, K.; Araki, Y.; Matsumoto, K.; Nakamura, T.; ;Yamagishi, H. Possible inhibition of cancer cell adhesion to the extracellular matrix in NK4-induced suppression of peritoneal implantation. Anticancer Res., 2005, 25(6B), 3847-3854.
70. Kubota, T.; Fujiwara, H.; Matsumura, A.; Taiyoh, H.; Ichikawa, I.; Okamoto, K.; Matsumoto, M.; Nakamura, T.; Otsuji, E. NK4, an HGF antagonist, prevents hematogenous pulmonary metastasis by inhibiting adhesion of CT26 cells to endothelial cells. Clin. Exp. Metastasis, 2009, 26(5), 447-456.
71. Kanehira, M.; Xin, H.; Hoshino, K.; Maemondo, M.; Mizuguchi, H.; Hayakawa, T.; Matsumoto, K.; Nakamura, T.; Nukiwa, T.; Saijo, Y. Targeted delivery of NK4 to multiple lung tumors by bone marrow-derived mesenchymal stem cells. Cancer Gene Ther., 2007, 14(11), 894-903. (Pubitemid 47557220)
72. Jie, J.Z.; Wang, J.W.; Qu, J.G.; Hung, T. Suppression of human colon tumor growth by adenoviral vector-mediated NK4 expression in an athymic mouse model. World J. Gastroenterol., 2007, 13(13), 1938-1946.
73. Tanaka, T.; Shimura, H.; Sasaki, T.; Narumi, K.; Maemondo, M.; Nukiwa, T.; Matsumoto, K.; Nakamura, T.; Ikeda, S. Gallbladder cancer treatment using adenovirus expressing the HGF/NK4 gene in a peritoneal implantation model. Cancer Gene Ther., 2004, 11(6), 431-440.
74. Hirao, S.; Yamada, Y.; Koyama, F.; Fujimoto, H.; Takahama, Y.; Ueno, M.; Kamada, K.; Mizuno, T.; Maemondo, M.; Nukiwa, T.; Matsumoto, K.; Nakamura, T.; Nakajima, Y. Tumor suppression effect using NK4, a molecule acting as an antagonist of HGF, on human gastric carcinomas. Cancer Gene Ther., 2002, 9(8), 700-707.
75. Heideman, D.A.M.; van Beusechem, A.W.; Bloemena, E.; Snijders, P.J.F.; Graanen, M.E.; Offenhaus, G.J.A.; Derksen, P.W.B.; de Bruin, M,.;Witlox, M.A.; Molenaar, B.; Meijer, C.J.L.M.; Gerritsen, W.R. Suppression of tumor growth, invasion and angiogenesis of human gastric cancer by adenovirus-mediated expression of NK4. J. Gene Med., 2004, 6(3), 317-327.
76. Ueda, K.; Iwahashi, M.; Matsuura, I.; Nakamori, M.; Nakamura, M.; Ojima, T.; Naka, T.; Ishida, K.; Matsumoto, K.; Nakamura, T.; Yamaue, H. Adenoviral-mediated Gene transduction of the hepatocyte growth factor (HGF) antagonist, NK4, suppresses peritoneal metastases of gastric cancer in nude mice. Eur. J. Cancer, 2004, 40(14), 2135-2142.
77. Fujiwara, H.; Kubota, T.; Amaike, H.; Inada, S.;Takashima, K.; Atsuji, K.; Yoshimura, M.; Maemondo, M.; Narumi, K.; Nukiwa, T.; Matsumoto, K.; Nakamura, T.; Hagiwara, A.; Yamagishi, H. Suppression of peritoneal implantation of gastric cancer cells by adenovirus vector-mediated NK4 expression. Cancer Gene Ther., 2005, 12(2), 206-216.
78. Namiki, Y.; Namiki, T.; Yoshida, H.; Date, M.; Yashiro, M.; Matsumoto, K.; Nakamura, T.; Yanagihara, K.; Tada, N.; Satoi, J.; Fujise, K. Preclinical study of a "tailor-made" combination of NK4- expressing gene therapy and gefitinib (ZD1839, Iressatrade mark) for disseminated peritoneal scirrhous gastric cancer. Int. J. Cancer, 2006, 118(6), 1545-1555.
79. Brockmann, M.A.; Papadimitriou, A.; Brandt, M.; Fillbrandt, R.; Westphal, M.; Lamszus, K. Inhibition of intracerebral glioblastoma growth by local treatment with the scatter factor/hepatocyte growth factor-antagonist NK4. Clin. Cancer Res., 2003, 9(12), 4578-4585.
80. Heideman, D.A.; Overmeer, R.M.; van Beusechem, V.W.; Lamers, W.H.; Hakvoort, T.B.; Snijders, P.J.; Craanen, M.E.; Offerhaus, G.J.; Meijer, C.J.; Gerritsen, W.R. Inhibition of angiogenesis and HGF-cMET-elicited malignant processes in human hepatocellular carcinoma cells using adenoviral vector-mediated NK4 gene therapy. Cancer Gene Ther., 2005, 12(12), 954-1629
81. Son, G.; Hirano, T.; Seki, E.; Iimuro, Y.; Nukiwa, T.; Matsumoto, K.; Nakamura, T.; Fujimoto, J. Blockage of HGF/c-Met system by gene therapy (adenovirus-mediated NK4 gene) suppresses hepatocellular carcinoma in mice. J. Hepatol., 2006, 45(5), 688-695.
82. Kushibiki, T.; Matsumoto, K.; Nakamura, T.; Tabata, Y. Suppression of tumor metastasis by NK4 plasmid DNA released from cationized gelatin. Gene Ther., 2004, 11(15), 1205-1214. (Pubitemid 39136784)
83. Kishi, Y.; Kuba, K.; Nakamura, T.; Wen, J.; Suzuki, Y.; Mizuno, S.; Nukiwa, T.; Matsumoto, K.; Nakamura, T. Systemic NK4 gene therapy inhibits tumor growth and metastasis of melanoma and lung carcinoma in syngeneic mouse tumor models. Cancer Sci., 2009, 100(7), 1351-1358.
84. Maemondo, M.; Saijo, Y.; Narumi, K.; Kikuchi, T.; Usui, K.; Tazawa, R.; Matsumoto, K.; Nakamura, T.; Sasaki, K.; Takahashi, M.; Niitsu, Y.; Nukiwa, T. Gene therapy with secretory leukoprotease inhibitor promoter-controlled replication-competent adenovirus for non-small cell lung cancer. Cancer Res., 2004, 64(13), 4611-4620.
85. Wang, W.; Li, Q.; Matsumoto, K.; Kayano, Y.; Matsumoto, I.; Oda, M.; Watanabe, G.; Nishioka, Y.; Sone, S.; Yano, S. Crosstalk to stromal fibroblasts induces resistance of lung cancer to EGFR tyrosine kinase inhibitors. Clin. Cancer Res., 2009, 15(21), 6630-6638.
86. Du, W.; Hattori, Y.; Yamada, T.; Matsumoto, K.; Nakamura, T.; Sagawa, M.; Otsuki, T.; Niikura, T.; Nukiwa, T.; Ikeda, Y. NK4, an antagonist of hepatocyte growth factor (HGF), inhibits growth of multiple myeloma cells: molecular targeting of angiogenic growth factor. Blood, 2007, 109(7), 3042-3049.
87. Saga, Y.; Mizukami, H.; Suzuki, M.; Urabe, M.; Kume, A.; Nakamura, T.; Sato, I.; Ozawa, K. Expression of HGF/NK4 in ovarian cancer cells suppresses intraperitoneal dissemination and extends host survival. Gene Ther., 2001, 8(19),1450-1455.
88. Tomioka, D.; Maehara, N.; Kuba, K.; Mizumoto, K.; Tanaka, M.; Matsumoto, K.; Nakamura, T. Inhibition of growth, invasion, and metastasis of human pancreatic carcinoma cells by NK4 in an orthotopic mouse model. Cancer Res., 2001, 61(20), 7518-7524.
89. Saimura, M.; Nagai, E.; Mizumoto, K.; Maehara, N.; Okino, H.; Katano, M.; Matsumoto, K.; Nakamura, T.; Narumi, K.; Nukiwa, T.; Tanaka, M. Intraperitoneal injection of adenovirus-mediated NK4 gene suppresses peritoneal dissemination of pancreatic cancer cell line AsPC-1 in nude mice. Cancer Gene Ther., 2002, 9(10), 799-806.
90. Maehara, N.; Nagai, E.; Mizumoto, K.; Sato, N.; Matsumoto, K.; Nakamura, T.; Narumi, K.; Nukiwa, T.; Tanaka, M. Gene transduction of NK4, HGF antagonist, inhibits in vitro invasion and in vivo growth of human pancreatic cancer. Clin. Exp. Metastasis, 2002, 19(5), 417-426. (Pubitemid 34876209)
91. Saimura, M.; Nagai, E.; Mizumoto, K.; Maehara, N.; Minamishima, Y.A.; Katano, M.; Matsumoto, K.; Nakamura, T.; Tanaka, M. Tumor suppression through angiogenesis inhibition by SUIT-2 pancreatic cancer cells genetically engineered to secrete NK4. Clin. Cancer Res., 2002, 8(10), 3243-3249.
92. Manabe, T.; Mizumoto, K.; Nagai, E.; Matsumoto, K.; Nakamura, T.; Nukiwa, T.; Tanaka, M.; Matsuda, T. Cell-based protein delivery system for the inhibition of the growth of pancreatic cancer: NK4 gene-transduced oral mucosal epithelial cell sheet. Clin. Cancer Res., 2003, 9(8), 3158-3166.
93. Ogura, Y.; Mizumoto, K.; Nagai, E.; Murakami, M.; Inadome, N.; Saimura, M.; Matsumoto, K.; Nakamura, T.; Maemondo, M.; Nukiwa, T.; Tanaka, M. Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival. Cancer Gene Ther., 2006, 13(5), 520-529.
94. Davies, G.; Mason, M.D.; Martin, T.A.; Parr, C.; Watkins, G.; Lane, J.; Matsumoto, K.; Nakamura, T.; Jiang, W.G. The HGF/SF antagonist NK4, reverses fibroblast- and HGF-induced prostate tumor growth and angiogenesis in vivo. Int. J. Cancer, 2003, 106(3), 348-354.
95. Gasparini, G.; Longo, R.; Toi, M.; Ferrara, N. Angiogenic inhibitors: a new therapeutic strategy in oncology. Nat. Clin. Pract. Oncol., 2005, 2(11), 562-577.
96. Casanovas, O.; Hicklin, D.J.; Bergers, G.; Hanahan, D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell, 2005, 8(4), 299-309.